I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Macular Telangiectasia Type 2: Protecting Your Central Vision
What Is Macular Telangiectasia Type 2
MacTel type 2 is a disease of the macula, the small central region of the retina responsible for your sharpest, most detailed vision. It involves gradual changes to tiny blood vessels in the fovea, which is the very center of the macula, and a slow loss of the specialized retinal cells that support vision in that area.
MacTel type 2 was once thought to be primarily a blood vessel disease. Research now shows it is fundamentally a neurodegenerative condition, meaning it involves the progressive loss of specialized cells in the retina. The cells most affected are called Muller cells, which play a critical supporting role in retinal health. As these cells deteriorate over time, the tissue of the macula gradually thins and may develop scarring.
As the disease progresses, the small blood vessels around the fovea can become abnormal and begin to leak fluid or blood. In some patients, new, fragile blood vessels grow beneath the retina, a complication called macular neovascularization. Leaking from these vessels can cause the macula to swell, blurring central vision. Over time, thinning and scarring of macular tissue lead to a gradual loss of fine-detail vision.
Importantly, MacTel type 2 does not affect side vision. Most patients retain their peripheral vision throughout the course of the disease. However, central vision loss affecting tasks like reading, recognizing faces, and driving typically progresses over a period of 10 to 20 years.
MacTel type 2 is sometimes mistaken for age-related macular degeneration or diabetic macular edema because all three conditions affect the macula. The key difference lies in the underlying cause. MacTel type 2 involves Muller cell degeneration and distinctive changes to the tiny vessels at the fovea, rather than the drusen deposits seen in macular degeneration or the blood sugar-related damage seen in diabetic eye disease. The pattern of retinal thinning visible on imaging also differs from these other conditions. A retina specialist can distinguish MacTel type 2 from other macular diseases through a combination of examination findings and imaging results.
Who Is at Risk for MacTel Type 2
MacTel type 2 can affect a wide range of adults, but certain factors make it more likely to develop or to go undetected for longer. Understanding who is at risk helps guide decisions about screening and monitoring.
MacTel type 2 most often develops in adults over the age of 40. Both men and women develop the condition, though some research suggests women may be slightly more commonly affected. The disease becomes more detectable with age, in part because high-resolution retinal imaging has improved the ability to identify subtle early changes that were previously missed.
MacTel type 2 is more prevalent than once thought. Studies estimate it affects roughly 1 in 1,000 adults aged 40 and older, and many cases likely go undiagnosed because the early stages produce no symptoms. As high-resolution retinal imaging has become more widely available, more cases are being identified that would previously have been missed or misclassified.
Certain whole-body health conditions are frequently found alongside MacTel type 2. Research suggests that a significant proportion of patients also have at least one of the following:
- Diabetes
- High blood pressure (hypertension)
- Obesity
- Cardiovascular disease
Managing these conditions does not cure MacTel type 2, but maintaining overall health is an important part of your comprehensive care.
MacTel type 2 is a bilateral disease, meaning it develops in both eyes. However, the two eyes rarely progress at the same rate. One eye may show more advanced changes while the other remains at an earlier stage. This asymmetry can make the condition harder to notice at first, because the less affected eye often compensates for the one that has changed more significantly.
Recognizing the Symptoms
MacTel type 2 is a slow-moving disease, and noticeable symptoms may not appear until the condition has already caused measurable retinal changes. Knowing what to watch for can help you seek care at the right time.
In the earliest phase of MacTel type 2, most people experience no noticeable changes in their vision. The condition is usually detected only during a comprehensive dilated eye exam or through retinal imaging. Because the disease develops gradually over many years, subtle changes are easy to overlook without regular professional eye care.
As MacTel type 2 advances, central vision may begin to shift in ways that become apparent during everyday tasks. Common symptoms include:
- Blurring of central vision
- Distorted vision where straight lines appear wavy or bent
- Difficulty reading or seeing fine print clearly
- A need for much brighter light to read or perform close work
- A gradual dimming or fading of central vision in one or both eyes
These changes often develop slowly over months or years. They may be subtle at first, especially when one eye is more affected than the other.
If new, abnormal blood vessels form beneath the retina, symptoms can worsen more quickly than the typical slow course of the disease. Leaking or bleeding from these vessels may cause a sudden blurring of central vision or the appearance of a new dark or gray area in the center of sight. If you notice a sudden or rapid change in your vision, contact a retina specialist promptly. While MacTel type 2 normally progresses slowly, neovascular complications can change quickly and benefit from timely evaluation and treatment.
How MacTel Type 2 Is Diagnosed
Diagnosing MacTel type 2 requires a thorough retinal examination combined with specialized imaging. Our team uses advanced diagnostic tools to detect and monitor even the most subtle retinal changes with precision.
A retina specialist begins by examining the back of the eye through dilated pupils, which allows a direct view of the macula and fovea. In MacTel type 2, the specialist may observe characteristic findings such as a subtle grayish or reddish discoloration around the fovea, small crystalline deposits within the retinal layers, or areas of pigment clumping near the center of the macula. These findings provide important diagnostic clues, even when they are subtle.
Optical coherence tomography, or OCT, is the most important imaging tool for diagnosing and monitoring MacTel type 2. OCT is a noninvasive scan that creates highly detailed cross-sectional images of the retina, similar in concept to an ultrasound but using light rather than sound waves. In MacTel type 2, OCT typically reveals thinning of the central retina, tiny cavities or spaces within the retinal layers, and loss of photoreceptors, the light-sensing cells essential for sharp vision. These findings help confirm the diagnosis and allow your specialist to track changes precisely over time.
Fluorescein angiography involves injecting a safe dye into a vein in the arm. As the dye travels through the blood vessels of the retina, a specialized camera captures images that reveal how those vessels are behaving. In MacTel type 2, this test can show the characteristic leakage pattern of abnormal foveal vessels and identify whether macular neovascularization has developed. It remains a valuable tool when the diagnosis is uncertain or when neovascularization is suspected.
OCT angiography, or OCTA, is a newer imaging method that maps blood flow in the retina without the need for a dye injection. By detecting motion within the blood vessels, OCTA can reveal subtle vascular changes around the fovea and identify early neovascularization at a stage when other tests might not yet show it clearly. Our team uses OCTA alongside standard OCT to build a more complete picture of each patient's retinal health, enabling earlier detection of any disease activity.
Treatment Options for MacTel Type 2
For most of its history, MacTel type 2 had no approved treatment, and care focused primarily on monitoring and managing complications. That changed with the first FDA approval specifically for this condition. Our team stays at the forefront of emerging therapies to offer patients the most current options available.
The FDA approved revakinagene taroretcel-lwey (ENCELTO) as the first and only treatment specifically approved for adults with MacTel type 2. ENCELTO is an encapsulated cell therapy, meaning it uses a small, surgically implanted capsule, roughly the size of a grain of rice, that is placed inside the eye by a retina specialist during a surgical procedure.
The capsule contains living cells that have been engineered to continuously produce and release a protective protein called recombinant human ciliary neurotrophic factor, or rhCNTF. This protein acts directly on retinal tissue, supporting the health of Muller cells and photoreceptors and slowing the progressive loss of these critical structures. Clinical trials demonstrated that ENCELTO significantly reduced the rate of photoreceptor loss over a 24-month period compared to untreated patients, representing a meaningful step forward in preserving vision for people with this condition.
It is important to understand that ENCELTO is designed to slow further cell loss, not to restore vision that has already been lost. Starting treatment before significant damage has occurred may help preserve more functional vision over the long term. Your retina specialist will assess whether ENCELTO is appropriate based on your individual stage of disease, retinal imaging, and overall health.
When MacTel type 2 leads to macular neovascularization, anti-VEGF injections are often recommended. VEGF stands for vascular endothelial growth factor, a chemical signal in the body that drives the growth of abnormal new blood vessels beneath the retina. Anti-VEGF medications block this signal, reducing the growth of new vessels, limiting leakage, and helping decrease swelling in the macula.
These medications are delivered by injection directly into the eye, a procedure performed in the office using numbing drops. Multiple anti-VEGF agents are available, and your retina specialist will recommend the most appropriate option based on your specific situation. Research has shown that anti-VEGF treatment can cause abnormal vessels to shrink and may help stabilize or modestly improve visual acuity in patients with neovascular MacTel type 2.
In patients with very early disease, or when active treatment is not yet indicated, a retina specialist may recommend a period of close monitoring rather than immediate intervention. This typically involves OCT imaging every few months to track any changes in retinal structure. Staying on schedule with these appointments is essential, because detecting progression early allows treatment decisions to be made before additional vision loss occurs.
Living Well with MacTel Type 2
While MacTel type 2 is a lifelong condition, many people continue to function well and maintain meaningful independence for years. The right practical strategies and the right support can make a significant difference in your quality of life at every stage.
Because MacTel type 2 affects central vision while leaving side vision intact, many daily activities remain manageable, especially in the earlier stages. The following approaches can help you make the most of your remaining vision:
- Use bright, focused lighting for reading and detailed close work
- Try large-print books or e-readers with adjustable font sizes
- Use magnifying devices recommended by a low vision specialist
- Experiment with positioning screens or reading material to take advantage of the clearest part of your vision
A low vision specialist can work with you to identify tools and techniques tailored specifically to your current vision level and daily needs.
Because diabetes, high blood pressure, obesity, and cardiovascular disease are commonly associated with MacTel type 2, keeping these conditions well managed is an important part of your comprehensive care. Work closely with your primary care physician to maintain healthy blood sugar, blood pressure, and weight. While managing systemic conditions may not stop MacTel type 2 from progressing, it supports your overall health and reduces the risk of additional complications.
A diagnosis of progressive central vision loss can understandably cause anxiety, frustration, or a sense of grief. These reactions are completely normal and deserve attention alongside your medical care. Low vision rehabilitation services can teach you practical new approaches to everyday tasks. Support groups for people with macular conditions offer the opportunity to connect with others who understand your experience firsthand. Do not hesitate to ask your retina specialist about referrals to these kinds of resources.
When to See a Retina Specialist
Knowing when to seek an evaluation and how to recognize symptoms that need urgent attention is a critical part of managing MacTel type 2. Our team is available to see both newly referred and self-referred patients and is equipped to address urgent retinal concerns when they arise.
If you are over 40 and have diabetes, high blood pressure, or a family history of macular disease, regular dilated eye exams are strongly advisable. Because MacTel type 2 causes no symptoms in its earliest stages, a thorough examination with retinal imaging is the only reliable way to detect it before vision loss has already begun. Catching the disease early gives your retina specialist the opportunity to monitor it closely and make timely, well-informed decisions about treatment.
Contact a retina specialist soon if you notice any of the following changes in your vision:
- New or worsening blurriness in your central vision
- Straight lines appearing wavy or distorted
- Increasing difficulty reading, even in good lighting
- A dark, gray, or blank area appearing in the center of your vision
These changes can signal disease progression or the development of neovascularization, both of which benefit from timely evaluation rather than a wait-and-see approach.
If you experience a sudden and significant loss of central vision, a sharp increase in floaters, or flashes of light, seek evaluation from a retina specialist or an emergency eye care provider as soon as possible. While these symptoms may not always be related to MacTel type 2, they can indicate other serious retinal conditions, such as a retinal tear or detachment, that require urgent care to prevent permanent vision loss.
Frequently Asked Questions
Here are answers to questions we commonly hear from patients who are newly diagnosed with or concerned about MacTel type 2.
Yes, and this is one of the strongest arguments for maintaining regular dilated eye exams. Imaging tools such as OCT can reveal the earliest structural changes in the macula well before any vision changes become noticeable to the patient. If you have risk factors such as being over 40 with diabetes or high blood pressure, proactive screening gives your care team the opportunity to detect and monitor the disease at the stage where protective measures are most valuable. Waiting until symptoms appear means some retinal cell loss has already occurred.
ENCELTO is designed to protect remaining photoreceptors and slow the rate of further cell loss, not to reverse damage that has already occurred. If retinal cells have already been lost, they cannot currently be restored. This makes early diagnosis and timely treatment discussion especially important. The more functional vision there is to preserve at the start of treatment, the more meaningful the benefit of slowing further loss can be. Your retina specialist will review your retinal imaging and current visual function to help determine whether you are a candidate and what realistic expectations look like for your individual situation.
MacTel type 2 does not typically cause total blindness. Because the disease targets the central retina while leaving peripheral vision intact, most patients retain the ability to navigate their surroundings and perform many daily activities independently, even as the disease advances. The central vision loss that does occur can significantly affect tasks like reading, driving, and recognizing faces. With approved treatments now available, slowing that central vision loss has become a realistic goal for many patients when the disease is identified and managed appropriately.
No. Although both conditions affect the macula and can cause central vision loss, they are separate diseases with distinct causes, different appearances on imaging, and different treatment approaches. MacTel type 2 involves degeneration of Muller cells and abnormal changes to the tiny vessels at the fovea. Age-related macular degeneration involves drusen deposits and a different pattern of retinal damage. Accurate diagnosis matters because the treatment path for each condition differs significantly. A retina specialist can perform the examination and imaging necessary to distinguish between these and other macular diseases with confidence.
The frequency of your visits depends on the stage of your disease and whether you are receiving active treatment. In a monitoring-only phase, visits with OCT imaging are typically scheduled every three to six months. After ENCELTO implant placement, more frequent visits are generally needed in the early months to assess the implant and monitor the retinal response. If anti-VEGF injections are required for neovascularization, appointments often occur every four to eight weeks. Your retina specialist will build a schedule tailored specifically to your situation and will adjust it over time based on how your retina is responding.
Driving ability depends on how much central vision has been affected and whether both eyes are involved to a significant degree. In the earlier stages, many patients continue to drive safely and legally. As central vision declines in both eyes, driving may eventually become unsafe or may no longer meet your state's legal vision requirements for licensure. If you have questions or concerns about driving, your retina specialist can give you an honest assessment of your current visual function, and a low vision specialist can discuss adaptive strategies and alternative transportation options if needed.
Expert Retinal Care at New England Retina Associates
Our team at New England Retina Associates is dedicated to providing expert, compassionate retinal care to patients throughout Connecticut, from early diagnosis and careful monitoring through advanced surgical and medical treatment. We bring together fellowship-trained vitreoretinal surgeons, state-of-the-art imaging technology, and access to the most current therapies to give each patient the best possible opportunity to preserve their sight. If you have been diagnosed with MacTel type 2 or have concerns about your central vision, we welcome you to schedule a consultation at any of our four convenient locations.
30 Years of Care & Commitment
